Robert Coleman, MD

The University of Texas MD Anderson Cancer Center

ColemanDr. Coleman is professor of gynecologic oncology and Vice-Chair, Clinical Research at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Coleman received his doctor of medicine degree from Creighton University in Omaha, Nebraska and completed his obstetrics/gynecology residency at Northwestern University Medical Center in Chicago, Illinois. Dr. Coleman completed his fellowship at The University of Texas MD Anderson Cancer Center.

Dr. Coleman’s research interests include novel therapeutics for ovarian, uterine, and cervical cancer, clinical trial development and statistical design, surgical innovations, and graduate education. He is the institution’s Gynecologic Oncology Group (GOG) principal investigator (PI), serves on the GOG’s Ovarian and Developmental Therapeutics Committees, and is PI or co-PI for several GOG prospective clinical trials including a national, multicenter, randomized trial evaluating chemotherapy and surgery for recurrent ovarian cancer, several trials of novel chemotherapeutics and biologics in cancers of the ovary, cervix, and uterus, and 2 trials evaluating lymphatic mapping for gynecologic malignancies. He currently is a co-project leader for the MDACC Ovarian SPORE, the MDACC Uterine SPORE, the Ovarian Cancer Research Fund, and the Marcus Foundation, each of which is sponsoring novel therapeutics trials in gynecologic cancers.

Dr. Coleman has authored or coauthored over 400 scientific publications, including over 160 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks including, The Handbook of Gynecologic Oncology, Clinical Lymphatic Mapping in Gynecologic Cancers, Prognostic and Predictive Factors in Gynecological Cancers, and Atlas of Gynecologic Oncology. Dr. Coleman serves as the chairman of the Department of Gynecologic Oncology Research Administration Committee and is a member of the Blanton-Davis Ovarian Cancer Research Program Executive Committee. Dr. Coleman has also served as a member of the Board of Directors for the Foundation for Women’s Cancer (formerly, the Gynecologic Cancer Foundation) and serves on the Council of the Society of Gynecologic Oncologists. In June 2010 he was appointed to the Ann Rife Cox Chair in Gynecology and is a member of the MDACC Center for RNA Interference and Non-Coding RNA.

Spotlight

Visit the Sisterhood of Survivorship page to read “Dena’s Story” — by a vulvar cancer survivor who has shared her story and wise words, and channeled her energy into her National Race to End Women’s Cancer team.

Awareness

Vaccine efficacy against vulvar infection with HPV 16/18 was comparable to the efficacy found against cervical infection 4 years after vaccination, according to researchers with the National Cancer Institute.

Research

The Foundation has published its 2014-2015 Research Grants and Awards Booklet with Applications. Please consider applying to become part of an elite group of physician-scientists committed to the well-being of women at risk for/affected by gyn malignancies.

Education

The next Ovarian Cancer Survivors Course will be Saturday, July 26, 2014 in Boston. For more information on courses, click here.